Free Trial
→ New Rule Hits in July — The Smart Money Already Moved (From American Alternative) (Ad)
LON:GSK

GSK 10/30/2024 Earnings Report

GSK logo
GBX 1,436.50 -15.09 (-1.04%)
As of 11:30 AM Eastern
ProfileEarnings HistoryForecast

GSK EPS Results

Actual EPS
GBX 49.70
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GSK Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GSK Announcement Details

Quarter
Date
10/30/2024
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

GSK Earnings Headlines

GSK and Dalhousie University Collaborate to Address Health Equity Gaps through the GSK Vaccinology and Health Equity Fellowship Award
June 18 at 4:46 PM | finance.yahoo.com
GSK slides Monday, underperforms market
June 16 at 1:53 PM | marketwatch.com
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
June 19, 2025 | American Alternative (Ad)
Bharat Biotech in-licences GSK’s Shigella vaccine
June 13, 2025 | msn.com
GSK's RSV drug Arexvy accepted for regulatory review in Europe
June 13, 2025 | lse.co.uk
GSK applies to EU regulator for expanded use of RSV vaccine
June 13, 2025 | msn.com
See More GSK Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GSK? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GSK and other key companies, straight to your email.

About GSK

GSK (LON:GSK), together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

View GSK Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles